Gain Therapeutics(GANX)
$1.18+0.24 (+25.53%)
GANX
Gain Therapeutics financials statements
$1.18
At close:+0.24 (+25.53%)
Want to see GANX full AI Analyst Report?
Gain Therapeutics (GANX) Ratios
470 Followers
Gain Therapeutics Ratios
GANX's free cash flow for Q3 2026 was $-3.05M. For the 2026 fiscal year, GANX's free cash flow was increased by $0.00 and operating cash flow was $-3.05M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.63 | 2.97 | 3.59 | 5.11 | 14.78 |
| Quick Ratio | 6.63 | 2.97 | 3.59 | 5.11 | 14.78 |
| Cash Ratio | 6.22 | 2.66 | 2.38 | 1.77 | 14.45 |
| Solvency Ratio | -4.72 | -4.25 | -3.68 | -3.36 | -3.33 |
| Operating Cash Flow Ratio | -5.51 | -4.83 | -3.81 | -3.56 | -4.84 |
| Short-Term Operating Cash Flow Coverage | -183.06 | -171.30 | -158.81 | -135.87 | -119.10 |
| Net Current Asset Value | $ 17.98M | $ 6.82M | $ 11.75M | $ 15.87M | $ 33.55M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.05 | 0.06 | 0.05 | 0.04 |
| Debt-to-Equity Ratio | 0.04 | 0.09 | 0.08 | 0.07 | 0.05 |
| Debt-to-Capital Ratio | 0.04 | 0.08 | 0.08 | 0.06 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.04 | 0.03 | 0.03 | 0.02 |
| Financial Leverage Ratio | 1.23 | 1.65 | 1.48 | 1.28 | 1.12 |
| Debt Service Coverage Ratio | -198.94 | -184.50 | -187.28 | -165.10 | -133.17 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.01 | 0.01 | 0.02 | 0.01 |
| Interest Debt Per Share | 0.02 | 0.03 | 0.08 | 0.11 | 0.16 |
| Net Debt to EBITDA | 1.05 | 0.49 | 0.49 | 0.34 | 2.55 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 100.00% | -6114.63% | -5249.31% |
| EBIT Margin | 0.00% | 0.00% | -40328.26% | -13410.18% | -10332.05% |
| EBITDA Margin | 0.00% | 0.00% | -40176.79% | -13390.10% | -10320.49% |
| Operating Profit Margin | 0.00% | 0.00% | -40328.26% | -13402.48% | -10323.59% |
| Pretax Profit Margin | 0.00% | 0.00% | -40210.67% | -13191.92% | -10368.70% |
| Net Profit Margin | 0.00% | 0.00% | -40354.33% | -13262.02% | -10371.70% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -40354.33% | -13262.02% | -10371.70% |
| Net Income Per EBT | 104.46% | 102.70% | 100.36% | 100.53% | 100.03% |
| EBT Per EBIT | 103.15% | 97.66% | 99.71% | 98.43% | 100.44% |
| Return on Assets (ROA) | -88.35% | -168.36% | -119.66% | -72.99% | -35.63% |
| Return on Equity (ROE) | -108.60% | -278.10% | -177.03% | -93.17% | -39.90% |
| Return on Capital Employed (ROCE) | -96.12% | -247.80% | -162.91% | -89.00% | -37.95% |
| Return on Invested Capital (ROIC) | -95.04% | -239.88% | -158.86% | -87.52% | -37.62% |
| Return on Tangible Assets | -88.75% | -170.24% | -120.91% | -73.65% | -35.82% |
| Earnings Yield | -18.99% | -41.30% | -52.34% | -47.29% | -25.16% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.23 | 1.28 | 0.69 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 5.07 | 12.78 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.09 | 0.16 | 0.13 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Cash Conversion Cycle | 0.00 | 0.00 | 1604.58 | 213.85 | 504.11 |
| Days of Sales Outstanding | 0.00 | 0.00 | 1604.58 | 285.85 | 532.66 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 72.00 | 28.56 |
| Operating Cycle | 0.00 | 0.00 | 1604.58 | 285.85 | 532.66 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.56 | -0.82 | -1.45 | -1.24 | -1.22 |
| Free Cash Flow Per Share | -0.56 | -0.83 | -1.45 | -1.25 | -1.23 |
| Dividend Paid and CapEx Coverage Ratio | -9232716.00 | -839.10 | -1228.41 | -123.51 | -131.25 |
| Capital Expenditure Coverage Ratio | -9232716.00 | -839.10 | -1228.41 | -123.51 | -131.25 |
| Operating Cash Flow Coverage Ratio | -25.22 | -28.90 | -18.36 | -11.53 | -7.69 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -341.90 | -110.77 | -92.33 |
| Free Cash Flow Yield | -17.39% | -38.23% | -44.38% | -39.82% | -22.57% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.28 | -2.43 | -1.91 | -2.11 | -3.97 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 771.06 | 280.42 | 412.15 |
| Price-to-Book (P/B) Ratio | 5.72 | 6.73 | 3.38 | 1.97 | 1.59 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.75 | -2.62 | -2.25 | -2.51 | -4.43 |
| Price-to-Operating Cash Flow Ratio | -5.75 | -2.62 | -2.26 | -2.53 | -4.46 |
| Price-to-Earnings Growth (PEG) Ratio | 0.17 | 0.05 | -0.12 | -0.26 | -0.01 |
| Enterprise Value Multiple | -4.48 | -2.01 | -1.43 | -1.75 | -1.44 |
| Enterprise Value | 86.05M | 39.69M | 31.78M | 31.16M | 19.93M |
| EV to EBITDA | -4.48 | -2.01 | -1.43 | -1.75 | -1.44 |
| EV to Sales | 0.00 | 0.00 | 575.93 | 234.90 | 148.78 |
| EV to Free Cash Flow | -4.66 | -2.10 | -1.68 | -2.10 | -1.60 |
| EV to Operating Cash Flow | -4.66 | -2.10 | -1.68 | -2.12 | -1.61 |
| Tangible Book Value Per Share | 0.56 | 0.31 | 0.95 | 1.57 | 3.41 |
| Shareholders’ Equity Per Share | 0.56 | 0.32 | 0.97 | 1.59 | 3.43 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.04 | -0.03 | -0.00 | -0.01 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Net Income Per Share | -0.61 | -0.89 | -1.71 | -1.48 | -1.37 |
| Tax Burden | 1.04 | 1.03 | 1.00 | 1.01 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 0.98 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 208.78 | 63.78 | 54.87 |
| SG&A to Revenue | 0.00 | 0.00 | 195.50 | 71.21 | 50.97 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 59.06 | 11.51 | 6.27 |
| Income Quality | 0.92 | 0.92 | 0.85 | 0.84 | 0.89 |
Currency in USD

